Back to Search
Start Over
PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
- Source :
- HemaSphere, Vol 7, p e3278692 (2023)
- Publication Year :
- 2023
- Publisher :
- Wiley, 2023.
- Subjects :
- Diseases of the blood and blood-forming organs
RC633-647.5
Subjects
Details
- Language :
- English
- ISSN :
- 25729241
- Volume :
- 7
- Database :
- Directory of Open Access Journals
- Journal :
- HemaSphere
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.f25c7cb01f0949d49598ffa2e49b37f6
- Document Type :
- article
- Full Text :
- https://doi.org/10.1097/01.HS9.0000975996.32786.92